Assembly Biosciences Inc (NASDAQ:ASMB) was the recipient of unusually large options trading activity on Wednesday. Investors bought 605 call options on the stock. This represents an increase of 831% compared to the typical daily volume of 65 call options.
In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $49.37, for a total transaction of $49,370.00. Following the sale, the director now directly owns 20,465 shares in the company, valued at approximately $1,010,357.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 3,000 shares of company stock worth $141,270 over the last 90 days. Corporate insiders own 19.60% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. Jennison Associates LLC raised its holdings in Assembly Biosciences by 19.6% during the 4th quarter. Jennison Associates LLC now owns 2,120,300 shares of the biopharmaceutical company’s stock worth $95,944,000 after buying an additional 347,025 shares during the period. BlackRock Inc. grew its stake in shares of Assembly Biosciences by 19.6% during the 4th quarter. BlackRock Inc. now owns 1,078,097 shares of the biopharmaceutical company’s stock worth $48,784,000 after acquiring an additional 176,976 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Assembly Biosciences by 21.2% during the 2nd quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock worth $12,615,000 after acquiring an additional 107,065 shares in the last quarter. Perceptive Advisors LLC grew its stake in shares of Assembly Biosciences by 21.5% during the 4th quarter. Perceptive Advisors LLC now owns 536,626 shares of the biopharmaceutical company’s stock worth $24,282,000 after acquiring an additional 94,793 shares in the last quarter. Finally, Rock Springs Capital Management LP grew its stake in shares of Assembly Biosciences by 15.4% during the 4th quarter. Rock Springs Capital Management LP now owns 450,000 shares of the biopharmaceutical company’s stock worth $20,363,000 after acquiring an additional 60,000 shares in the last quarter. Hedge funds and other institutional investors own 66.34% of the company’s stock.
Several brokerages have commented on ASMB. BidaskClub upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Tuesday, January 30th. ValuEngine upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Zacks Investment Research downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Monday, January 15th. B. Riley began coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They set a “neutral” rating and a $35.00 target price on the stock. Finally, Jefferies Group began coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They set a “buy” rating and a $50.00 target price on the stock. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $39.25.
Shares of Assembly Biosciences (NASDAQ ASMB) opened at $55.79 on Friday. The company has a market cap of $1,124.50, a P/E ratio of -18.78 and a beta of 0.77. Assembly Biosciences has a fifty-two week low of $18.60 and a fifty-two week high of $58.68.
COPYRIGHT VIOLATION WARNING: “Investors Purchase High Volume of Call Options on Assembly Biosciences (ASMB)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/23/investors-purchase-high-volume-of-call-options-on-assembly-biosciences-asmb.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.